Ask about the exact use.
Check the specific finished medicine and its prescribing information. Approval of one product does not extend to every product with a similar ingredient.
Get started Home / Prescription peptide care
BNTRL / Prescription peptide care
The useful question is specific: which product, for which purpose, with what evidence and what follow-up?
Get peptide-care updatesU.S. online care is in development. Enrollment, prescribing and payments are not yet available.

Know the distinction
BNTRL’s planned U.S. offering focuses on FDA-approved prescription options when clinically appropriate.
Check the specific finished medicine and its prescribing information. Approval of one product does not extend to every product with a similar ingredient.
Compounded medicines are not FDA approved. FDA does not review them for safety, effectiveness or quality before marketing.
Do not treat “research use only” marketing as an approved prescription pathway. Discuss the exact product with a licensed clinician.
Further reading: FDA: concerns with unapproved GLP-1 drugs ↗
Read beyond the headline
Our learning hub links directly to outside sources so you can explore the background and discuss it with a clinician.
Explore the evidence guideQuestions, answered
No. “Peptide” is a broad category. Regulatory status depends on the specific product; a category name is not an approval.
The planned U.S. offering focuses on FDA-approved prescription options when clinically appropriate. No peptide products are currently sold or prescribed here.
No. Medication selection and dosing require an individual clinical assessment. BNTRL does not provide a self-prescribing or injection calculator.
Choose prescription peptide care in the interest form. The form records a contact request, not clinical enrollment.
Your next chapter
Stay informed about BNTRL’s planned prescription peptide offering.